A1BG-AS1 promotes adriamycin resistance of breast cancer by recruiting IGF2BP2 to upregulate ABCB1 in an m6A-dependent manner

被引:11
作者
Wang, Jian [1 ]
Xu, Jie [1 ]
Zheng, Jie [2 ]
机构
[1] Tianjin Fifth Cent Hosp, Dept Gen Surg, 41 Tanggu Zhejiang Rd,Binhai New Area, Tianjin 300450, Peoples R China
[2] Tianjin Fifth Cent Hosp, Dept Pathol, Tianjin 300450, Peoples R China
关键词
MULTIDRUG-RESISTANCE; EXPRESSION; CELLS;
D O I
10.1038/s41598-023-47956-2
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Adriamycin (ADR) resistance is an obstacle for chemotherapy of breast cancer (BC). ATP binding cassette subfamily B member 1 (ABCB1) expression is indicated to be closely related to the drug resistance of cancer cells. The current work intended to explore the molecular mechanisms to regulate ABCB1 in BC cells with ADR resistance. We found that long noncoding RNA (lncRNA) A1BG antisense RNA 1 (A1BG-AS1) is upregulated in ADR resistant BC cell lines (MCF-7/ADR, MDA-MB-231/ADR). A1BG-AS1 knockdown enhanced the ADR sensitivity by suppressing the viability, proliferation potential and migration ability, and facilitating cell apoptosis in BC. Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) is known to be an m6A reader to modulate the stability of mRNA transcripts in an m6A-dependent manner, which was a shared RNA binding protein (RBP) for A1BG-AS1 and ABCB1. The interaction of IGF2BP2 with A1BG-AS1 or ABCB1 was explored and verified using RNA pulldown and RNA immunoprecipitation (RIP) assays. ABCB1 mRNA and protein expression was positively regulated by A1BG-AS1 and IGF2BP2 in BC cells. ABCB1 mRNA expression was stabilized by A1BG-AS1 via recruiting IGF2BP2 in an m6A-dependent manner. Moreover, rescue assays demonstrated that A1BG-AS1 enhanced BC ADR resistance by positively modulating ABCB1. Xenograft mouse models were used to explore whether A1BG-AS1 affected the ADR resistance in BC in vivo. The findings indicated that A1BG-AS1 silencing inhibited tumor growth and alleviated ADR resistance in vivo. In conclusion, A1BG-AS1 enhances the ADR resistance of BC by recruiting IGF2BP2 to upregulate ABCB1 in an m6A-dependent manner.
引用
收藏
页数:13
相关论文
共 33 条
  • [1] Targeting signaling and apoptotic pathways involved in chemotherapeutic drug- resistance of hematopoietic cells
    Abrams, Stephen L.
    Ruvolo, Peter P.
    Ruvolo, Vivian R.
    Ligresti, Giovanni
    Martelli, Alberto M.
    Cocco, Lucio
    Ratti, Stefano
    Tafuri, Agostino
    Steelman, Linda S.
    Candido, Saverio
    Libra, Massimo
    McCubrey, James A.
    [J]. ONCOTARGET, 2017, 8 (44) : 76525 - 76557
  • [2] Mechanisms of Multidrug Resistance in Cancer Chemotherapy
    Bukowski, Karol
    Kciuk, Mateusz
    Kontek, Renata
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (09)
  • [3] Long non-coding RNA A1BG-AS1 promotes tumorigenesis in breast cancer by sponging microRNA-485-5p and consequently increasing expression of FLOT1 expression
    Cai, Shibin
    Zhou, Yi
    Pan, Ying
    Liu, Pengpeng
    Yu, Kaijie
    Chen, Shuzheng
    [J]. HUMAN CELL, 2021, 34 (05) : 1517 - 1531
  • [4] HIF-1α Inhibition Reverses Multidrug Resistance in Colon Cancer Cells via Downregulation of MDR1/P-Glycoprotein
    Chen, Jianfang
    Ding, Zhenyu
    Peng, Yonghai
    Pan, Feng
    Li, Jianjun
    Zou, Lan
    Zhang, Yanling
    Liang, Houjie
    [J]. PLOS ONE, 2014, 9 (06):
  • [5] The circular RNA circ-ERBIN promotes growth and metastasis of colorectal cancer by miR-125a-5p and miR-138-5p/4EBP-1 mediated cap-independent HIF-1α translation
    Chen, Liang-Yan
    Wang, Lian
    Ren, Yue-Xiang
    Pang, Zheng
    Liu, Yao
    Sun, Xiao-Dong
    Tu, Jian
    Zhi, Zheng
    Qin, Yan
    Sun, Li-Na
    Li, Jian-Ming
    [J]. MOLECULAR CANCER, 2020, 19 (01)
  • [6] Long non-coding RNAs in anti-cancer drug resistance
    Chen, Qin-nan
    Wei, Chen-chen
    Wang, Zhao-xia
    Sun, Ming
    [J]. ONCOTARGET, 2017, 8 (01) : 1925 - 1936
  • [7] Transcriptome Analysis Identifies GATA3-AS1 as a Long Noncoding RNA Associated with Resistance to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer Patients
    Contreras-Espinosa, Laura
    Alcaraz, Nicolas
    De La Rosa-Velazquez, Inti A.
    Diaz-Chavez, Jose
    Cabrera-Galeana, Paula
    Rebollar-Vega, Rosa
    Reynoso-Noveron, Nancy
    Maldonado-Martinez, Hector A.
    Gonzalez-Barrios, Rodrigo
    Montiel-Manriquez, Rogelio
    Bautista-Sanchez, Diana
    Castro-Hernandez, Clementina
    Alvarez-Gomez, Rosa M.
    Jimenez-Trejo, Francisco
    Tapia-Rodriguez, Miguel
    Garcia-Gordillo, Jose A.
    Perez-Rosas, Augusto
    Bargallo-Rocha, Enrique
    Arriaga-Canon, Cristian
    Herrera, Luis A.
    [J]. JOURNAL OF MOLECULAR DIAGNOSTICS, 2021, 23 (10) : 1306 - 1323
  • [8] Triple-negative breast cancer: Clinical features and patterns of recurrence
    Dent, Rebecca
    Trudeau, Maureen
    Pritchard, Kathleen I.
    Hanna, Wedad M.
    Kahn, Harriet K.
    Sawka, Carol A.
    Lickley, Lavina A.
    Rawlinson, Ellen
    Sun, Ping
    Narod, Steven A.
    [J]. CLINICAL CANCER RESEARCH, 2007, 13 (15) : 4429 - 4434
  • [9] N6-methyladenosine mediates the cellular proliferation and apoptosis via microRNAs in arsenite-transformed cells
    Gu, Shiyan
    Sun, Donglei
    Dai, Huangmei
    Zhang, Zunzhen
    [J]. TOXICOLOGY LETTERS, 2018, 292 : 1 - 11
  • [10] IGF2BP2 regulates DANCR by serving as an N6-methyladenosine reader
    Hu, Xiaoge
    Peng, Wan-Xin
    Zhou, Huaixiang
    Jiang, Jiahong
    Zhou, Xinchun
    Huang, Dongsheng
    Mo, Yin-Yuan
    Yang, Liu
    [J]. CELL DEATH AND DIFFERENTIATION, 2020, 27 (06) : 1782 - 1794